BioCryst Pharmaceuticals heads into its Q3 earnings release, due after the close tomorrow, with short sellers markedly less aggressive than six weeks ago and options traders showing little defensiveness despite the binary event ahead. The most striking feature of the positioning picture is the scale of short covering since early October. Short interest has fallen from roughly 36…
BCRX downgraded to Sector Perform from Outperform by RBC Capital; target cut to $11 from $13, implying 25% downside from $8.81 close.
Key data as of 4 Nov 2026
BioCryst Pharmaceuticals heads into its May 4 Q1 earnings call with short sellers rebuilding positions at pace — and options traders turning more defensive than at any point in recent memory. The week's most striking…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for BCRX — free to start on ORTEX.
Sign up for free →Open BCRX on ORTEX